Bortezomib and Gemcitabine in Treating Patients With Recurrent or Metastatic Nasopharyngeal Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well giving bortezomib together with gemcitabine works in
treating patients with recurrent or metastatic nasopharyngeal cancer. Bortezomib may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in
chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells,
either by killing the cells or by stopping them from dividing. Giving bortezomib together
with gemcitabine may kill more tumor cells